BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Westdijk J, Brugmans D, Martin J, Oever AV, Bakker WA, Levels L, Kersten G. Characterization and standardization of Sabin based inactivated polio vaccine: Proposal for a new antigen unit for inactivated polio vaccines. Vaccine 2011;29:3390-7. [DOI: 10.1016/j.vaccine.2011.02.085] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Westdijk J, van der Maas L, ten Have R, Kersten G. Measuring Poliovirus Antigenicity by Surface Plasmon Resonance. Application for Potency Indicating Assays. In: Martín J, editor. Poliovirus. New York: Springer; 2016. pp. 299-323. [DOI: 10.1007/978-1-4939-3292-4_16] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Kraan H, Ten Have R, van der Maas L, Kersten G, Amorij JP. Incompatibility of lyophilized inactivated polio vaccine with liquid pentavalent whole-cell-pertussis-containing vaccine. Vaccine 2016;34:4572-8. [PMID: 27470209 DOI: 10.1016/j.vaccine.2016.07.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
3 Sun M, Ma Y, Xu Y, Yang H, Shi L, Che Y, Liao G, Jiang S, Zhang S, Li Q. Dynamic profiles of neutralizing antibody responses elicited in rhesus monkeys immunized with a combined tetravalent DTaP-Sabin IPV candidate vaccine. Vaccine 2014;32:1100-6. [PMID: 24412578 DOI: 10.1016/j.vaccine.2013.12.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
4 Crawt L, Atkinson E, Tedcastle A, Pegg E, Dobly A, Wei C, Lei S, Ling P, Li C, Zheng J, Wang Y, Liqun H, Jorajuria S, Cozic G, Ugiyadi D, Kurniati N, Ochiai S, Miyazawa M, Someya Y, Nishihama T, Masafumi M, Westdijk J, Crowe S, Graaf MD, Kouiavskaia D, Chumakov K, Minor P, Cooper G, Rigsby P, Martin J; sIPV Study Group. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays. The Journal of Infectious Diseases 2019. [DOI: 10.1093/infdis/jiz076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
5 Thomassen YE, van Eikenhorst G, van der Pol LA, Bakker WAM. Isoelectric Point Determination of Live Polioviruses by Capillary Isoelectric Focusing with Whole Column Imaging Detection. Anal Chem 2013;85:6089-94. [DOI: 10.1021/ac400968q] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
6 Wan Y, Hickey JM, Bird C, Witham K, Fahey P, Forster A, Joshi SB, Volkin DB. Development of Stabilizing Formulations of a Trivalent Inactivated Poliovirus Vaccine in a Dried State for Delivery in the Nanopatch™ Microprojection Array. J Pharm Sci 2018;107:1540-51. [PMID: 29421219 DOI: 10.1016/j.xphs.2018.01.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Bockstal V, Tiemessen MM, Achterberg R, Van Wordragen C, Knaapen AM, Serroyen J, Marissen WE, Schuitemaker H, Zahn R. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine 2018;36:6979-87. [PMID: 30314910 DOI: 10.1016/j.vaccine.2018.09.068] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Shirato H, Someya Y, Ochiai M, Horiuchi Y, Takahashi M, Takeda N, Wakabayashi K, Ouchi Y, Ota Y, Tano Y, Abe S, Yamazaki S, Wakita T; sIPV Evaluation Group of NIID-Virology II. A national reference for inactivated polio vaccine derived from Sabin strains in Japan. Vaccine 2014;32:5163-9. [PMID: 25090648 DOI: 10.1016/j.vaccine.2014.07.065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
9 Song S, Liu Z, Zhou J, Cai W, Yang H, Ma L, Gao J, Li W, Liao G. An adjuvant compound that enhances immunogenicity at fractional doses of the Sabin-inactivated poliovirus vaccine (sIPV) with a long duration of protection in a rat model. J Med Virol 2019;91:14-21. [PMID: 30168587 DOI: 10.1002/jmv.25298] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Sanders BP, de Los Rios Oakes I, van Hoek V, Bockstal V, Kamphuis T, Uil TG, Song Y, Cooper G, Crawt LE, Martín J, Zahn R, Lewis J, Wimmer E, Custers JH, Schuitemaker H, Cello J, Edo-Matas D. Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine. PLoS Pathog 2016;12:e1005483. [PMID: 27032093 DOI: 10.1371/journal.ppat.1005483] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
11 Shimizu H. Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in Japan. Vaccine 2016;34:1975-85. [PMID: 25448090 DOI: 10.1016/j.vaccine.2014.11.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
12 Sanders BP, Oakes Ide L, van Hoek V, Liu Y, Marissen W, Minor PD, Wimmer E, Schuitemaker H, Custers JH, Macadam A, Cello J, Edo-Matas D. Production of high titer attenuated poliovirus strains on the serum-free PER.C6(®) cell culture platform for the generation of safe and affordable next generation IPV. Vaccine 2015;33:6611-6. [PMID: 26529068 DOI: 10.1016/j.vaccine.2015.10.091] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
13 Verdijk P, Rots NY, van Oijen MG, Oberste MS, Boog CJ, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults. Vaccine 2013;31:5531-6. [DOI: 10.1016/j.vaccine.2013.09.021] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
14 ten Have R, Westdijk J, Levels LM, Koedam P, de Haan A, Hamzink MR, Metz B, Kersten GF. Trypsin diminishes the rat potency of polio serotype 3. Biologicals 2015;43:474-8. [PMID: 26321654 DOI: 10.1016/j.biologicals.2015.07.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Hamidi A, Bakker WA. Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strains. Pharm Pat Anal 2012;1:589-99. [PMID: 24236927 DOI: 10.4155/ppa.12.70] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
16 Kraan H, Ploemen I, van de Wijdeven G, Que I, Löwik C, Kersten G, Amorij J. Alternative delivery of a thermostable inactivated polio vaccine. Vaccine 2015;33:2030-7. [DOI: 10.1016/j.vaccine.2015.03.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
17 Torisu T, Shikama S, Nakamura K, Enomoto K, Maruno T, Mori A, Uchiyama S, Satou T. Physicochemical Characterization of Sabin Inactivated Poliovirus Vaccine for Process Development. J Pharm Sci 2021;110:2121-9. [PMID: 33340531 DOI: 10.1016/j.xphs.2020.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
18 Qi W, Orgel S, Francon A, Randolph TW, Carpenter JF. Urea Improves Stability of Inactivated Polio Vaccine Serotype 3 During Lyophilization and Storage in Dried Formulations. Journal of Pharmaceutical Sciences 2018;107:2070-8. [DOI: 10.1016/j.xphs.2018.04.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
19 Minor PD. The polio-eradication programme and issues of the end game. J Gen Virol 2012;93:457-74. [PMID: 22128250 DOI: 10.1099/vir.0.036988-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kanojia G, ten Have R, Brugmans D, Soema PC, Frijlink HW, Amorij J, Kersten G. The effect of formulation on spray dried Sabin inactivated polio vaccine. European Journal of Pharmaceutics and Biopharmaceutics 2018;129:21-9. [DOI: 10.1016/j.ejpb.2018.05.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
21 Thomassen YE, van 't Oever AG, van Oijen MG, Wijffels RH, van der Pol LA, Bakker WA. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS One 2013;8:e83374. [PMID: 24349497 DOI: 10.1371/journal.pone.0083374] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
22 Karlsson R. Biosensor binding data and its applicability to the determination of active concentration. Biophys Rev 2016;8:347-58. [PMID: 28510014 DOI: 10.1007/s12551-016-0219-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
23 Abd-Elghaffar AA, Rashed ME, Ali AE, Amin MA. In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine. Vaccines (Basel) 2020;8:E601. [PMID: 33066050 DOI: 10.3390/vaccines8040601] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Nijst OE, Mouthaan JJ, Mekkes DR, Jusic E, van der Avoort HG, Metz B. Rapid and accurate identification of poliovirus strains used for vaccine production. Journal of Virological Methods 2013;189:189-95. [DOI: 10.1016/j.jviromet.2013.01.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine 2014;32:4938-44. [DOI: 10.1016/j.vaccine.2014.07.029] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
26 Wilton T. Methods for the Quality Control of Inactivated Poliovirus Vaccines. Methods Mol Biol 2016;1387:279-97. [PMID: 26983741 DOI: 10.1007/978-1-4939-3292-4_15] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Sanders B, Koldijk M, Schuitemaker H. Inactivated Viral Vaccines. In: Nunnally BK, Turula VE, Sitrin RD, editors. Vaccine Analysis: Strategies, Principles, and Control. Berlin: Springer Berlin Heidelberg; 2015. pp. 45-80. [DOI: 10.1007/978-3-662-45024-6_2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
28 Vidor E. Poliovirus Vaccine–Inactivated. Plotkin's Vaccines. Elsevier; 2018. pp. 841-865.e10. [DOI: 10.1016/b978-0-323-35761-6.00047-x] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
29 Kraan H, van Herpen P, Kersten G, Amorij JP. Development of thermostable lyophilized inactivated polio vaccine. Pharm Res 2014;31:2618-29. [PMID: 24760448 DOI: 10.1007/s11095-014-1359-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
30 Grover Shah V, Ray S, Karlsson R, Srivastava S. Calibration-free concentration analysis of protein biomarkers in human serum using surface plasmon resonance. Talanta 2015;144:801-8. [PMID: 26452893 DOI: 10.1016/j.talanta.2015.06.074] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
31 Verdijk P, Rots NY, Bakker WA. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Review of Vaccines 2014;10:635-44. [DOI: 10.1586/erv.11.51] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
32 Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 2013;31:1298-304. [PMID: 23313617 DOI: 10.1016/j.vaccine.2012.12.076] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
33 Vidor E, Plotkin SA. Poliovirus vaccine—inactivated. Vaccines. Elsevier; 2013. pp. 573-97. [DOI: 10.1016/b978-1-4557-0090-5.00034-3] [Cited by in Crossref: 25] [Article Influence: 3.1] [Reference Citation Analysis]
34 Qi W, Zeng Y, Orgel S, Francon A, Kim JH, Randolph TW, Carpenter JF, Russell Middaugh C. Preformulation Study of Highly Purified Inactivated Polio Vaccine, Serotype 3. Journal of Pharmaceutical Sciences 2014;103:140-51. [DOI: 10.1002/jps.23801] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
35 van der Maaden K, Trietsch SJ, Kraan H, Varypataki EM, Romeijn S, Zwier R, van der Linden HJ, Kersten G, Hankemeier T, Jiskoot W, Bouwstra J. Novel hollow microneedle technology for depth-controlled microinjection-mediated dermal vaccination: a study with polio vaccine in rats. Pharm Res 2014;31:1846-54. [PMID: 24469907 DOI: 10.1007/s11095-013-1288-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]